Table 2. Risk factors for early death (development data set).

	Univariate analysis			Multivariate analysis
Parameters	RR (eβ)	95% CI	P-value	RR (eβ)	95% CI	P-value
Age
40–49 vs <40	1.32	0.87–2.00	0.1816
50–59 vs <40	1.41	0.95–2.08	0.8450
⩾60 vs <40	1.77	1.21–4.61	0.0030
Gender: female vs male	1.04	0.80–1.35	0.7586
Performance status
1 vs 0	3.04	2.11–4.36	<.0001	3.83	2.06–7.12	<.0001
2–3 vs 0	10.00	6.62–14.82	<.0001	12.00	5.53–26.06	<.0001
Interval a
Q2 vs Q1	0.80	0.55–1.17	0.2618
Q3 vs Q1	0.87	0.63–1.20	0.4528
Q4 vs Q1	0.41	0.27–0.61	<.0001
Histological subtype
MFH vs leiomyo	1.32	0.82–2.10	0.244
Fibro vs leiomyo	0.59	0.21–1.68	0.325
Lipo vs leiomyo	0.72	0.38–1.33	0.314
Angio vs leiomyo	0.94	0.36–2.44	0.899
Syno vs leiomyo	0.23	0.08–0.65	0.005
MPNST vs leiomyo	0.48	0.21–1.07	0.074
Rhabdo vs leiomyo	0.95	0.59–1.15	0.818
Unclassified vs leiomyo	1.20	0.65–2.21	0.558
Other vs leiomyo	0.91	0.40–2.06	0.826
Grade
II vs	1.39	0.77–2.95	0.2749
III v I	1.99	1.13–3.49	0.0164
Primary site
Head/neck vs limb	1.88	0.88–4.00	0.1029
Trunk vs limb	1.54	1.03–2.30	0.0338
Viscera vs limb	1.61	1.06–2.45	0.0249
Lung met.: yes vs no	1.07	0.83–1.40	0.5706
Liver met.: yes vs no	1.57	1.19–2.14	0.0041	2.377	1.39–4.05	0.0014
Bone met.: yes vs no	1.13	0.73–1.74	0.5690
Other met.: yes vs no	1.50	1.12–2.01	0.0061	2.002	1.22–3.27	0.0055

Abbreviations: CI=confidence interval; RR=relative risk; MHF=malignant histiocytofibroma; MPNST=malignant peripheral nerve sheath tumour; met.=metastasis.

^aQ1: 0–60 days; Q2: 61–180 days; Q3: 181–540 days; and Q4:>540 days.